What is leptin and how does it signal body fat levels to the brain?

Leptin is a hormone exclusively produced by fat (adipose) tissue. Its production is directly proportional to the amount of body fat. Leptin levels in the blood act as a signal to the brain, specifically to neurons with leptin receptors in the hypothalamus, indicating the body's energy reserves and influencing hunger levels.

Why did early leptin treatments for obesity fail?

Leptin treatments initially failed because most obese individuals already have high leptin levels and exhibit leptin resistance, similar to insulin resistance in type 2 diabetes. The treatment was effective for a small subset of individuals with naturally low leptin or after significant weight loss when leptin levels had plummeted.

How do AGRP neurons predict how much food an animal will eat?

AGRP neurons in the hypothalamus respond rapidly to the sight and smell of food and other cues. They integrate information about palatability, accessibility, and current hunger levels to predict, within seconds, how much an animal is likely to eat in an upcoming meal. This anticipatory response helps initiate satiety even before consumption begins.

What is the role of genetics in obesity?

Body weight regulation is highly inheritable, with estimates around 80% attributed to genetics. While environment shifts the average body weight of a population, individual predisposition to being lean or obese is largely genetic. Mutations in pathways involving AGRP/POMC neurons and their receptors are linked to severe obesity in a significant percentage of cases.

How do ultra-processed foods contribute to overeating?

Research by Kevin Hall shows that even when ultra-processed foods are rated as equally palatable as whole foods, people tend to eat more of them and gain weight. This could be due to their optimized fat, sugar, and protein percentages that promote consumption, or because they are less volumetric and require less energy to digest, leading to reduced satiety signals.

What is the 'incretin effect' and how did it lead to GLP-1 drug development?

The incretin effect is the observation that oral glucose produces a stronger insulin response than intravenous glucose, suggesting gut-derived factors (incretins) amplify insulin release. GLP-1 was identified as an incretin, and its ability to boost insulin responses, combined with the discovery of more stable GLP-1 analogs from sources like the Gila monster, led to the development of diabetes and weight-loss drugs.

How do Ozempic and similar GLP-1 drugs work to suppress appetite and promote weight loss?

These drugs are GLP-1 agonists that dramatically increase the concentration of GLP-1 in the blood (thousandfold or more) for extended periods (e.g., 7-day half-life for semaglutide). They primarily suppress appetite by activating GLP-1 receptors on neurons in the brainstem, particularly the nucleus of the solitary tract (NTS) and area postrema (AP), which process signals from the gut.

What are the new frontiers in anti-obesity drug development beyond GLP-1?

Beyond current GLP-1 drugs like Ozempic, new compounds include GLP-1 'plus' drugs that are dual or triple agonists, also targeting GIP and glucagon. For example, tirzepatide (Mounjaro/Zepbound) is a GLP-1/GIP dual agonist showing even greater weight loss. Triple agonists (GLP-1/GIP/glucagon) are in trials, aiming to further reduce appetite and increase energy expenditure for bariatric-surgery-level weight loss.

What is dopamine's true role in food and eating behavior?

Dopamine is primarily involved in motivation ('wanting') to obtain food, especially when effort is required, and in learning about environmental cues that predict food availability. It is less involved in the momentary pleasure ('liking') derived from eating. Dopamine also plays a slower, delayed role in learning to associate the taste and flavor of food with its post-ingestive effects and nutritional benefits.

How does the brain use dopamine signals to learn about hydration from food?

The brain has specific dopamine neuron populations that respond to internal signals, such as when blood is rehydrated. This delayed dopamine signal, occurring after fluid ingestion, helps animals learn to associate specific food flavors with their rehydrating effects, which is crucial for survival, especially for animals that obtain most of their water from food.

How does the brain regulate thirst and water intake?

Thirst is regulated by specialized osmosensor neurons in specific forebrain regions (circumventricular organs like the subfornical organ), which are highly sensitive to blood osmolality (salt concentration). These neurons receive input from the mouth (tracking water volume consumed) and compare it with blood osmolality to predict when rehydration will occur, allowing thirst to be quenched rapidly, even before full hydration.

Can mindset or perception influence satiety and food intake?

Yes, human perception and mindset significantly modulate physiological responses to food. Studies show that being told a milkshake is calorically dense versus sparse can alter hormone responses related to satiety, even if the actual caloric content is the same. Understanding a food's nutritious value can also partially offset the perceived 'pain' of caloric restriction.

What are some simple, science-backed recommendations for healthy eating?

Key recommendations include limiting ultra-processed foods in favor of whole foods for better satiation and reduced 'engineered palatability,' ensuring adequate protein consumption (due to protein leveraging, satiating effects, and higher thermic effect), and drinking water to distinguish between hunger and thirst.

Key Moments

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

Andrew Huberman

Science & Technology5 min read139 min video

Jun 17, 2024|395,560 views|8,583|629

andrew huberman huberman lab podcast huberman podcast dr. andrew huberman neuroscience huberman lab andrew huberman podcast the huberman lab podcast science podcast zachary knight dr zachary knight Wegovy

Save to Pod

Key Moments

TL;DR

Dr. Knight discusses the science of hunger, satiety, and thirst, dopamine's role, and obesity drugs like GLP-1 agonists.

Key Insights

Hunger and satiety are regulated by distinct short-term (brainstem) and long-term (hypothalamus) neural circuits that interact.

Leptin, a hormone produced by fat cells, signals body fat reserves to the brain, and dysfunction leads to leptin resistance in obesity.

Dopamine is crucial for motivation to seek food and for learning predictive cues, rather than for the pleasure of eating itself.

GLP-1 agonists, like Ozempic and Mounjaro, suppress appetite by acting on brainstem centers (NTS and area postrema) via mechanisms distinct from natural biological levels.

Genetic predisposition plays a significant role in body weight regulation, interacting with environmental factors like food availability and ultra-processed foods.

Thirst and salt appetite are distinct but linked systems for maintaining fluid and electrolyte balance, involving specialized brain circuits and predictive mechanisms.

NEURAL CIRCUITS CONTROLLING FEEDING BEHAVIOR

Dr. Zachary Knight explains that feeding behavior is governed by two interacting systems: a short-term system in the brainstem managing meal size and timing, and a long-term system in the hypothalamus tracking body fat reserves. Experiments like the 'decerebrate rat' demonstrated that the brainstem alone can regulate meal termination signals, while the forebrain is crucial for adjusting intake based on long-term energy needs. This highlights the brain's complex, multi-faceted control over appetite.

THE ROLE OF LEPTIN AND BODY FAT HOMEOSTASIS

Body fat serves as a critical energy reserve, and its level is signaled to the brain primarily by the hormone leptin. Leptin is exclusively produced by fat tissue, and its blood levels are proportional to body fat mass. The discovery of leptin stemmed from studying obese mutant mice and revealed that individuals with obesity often have high leptin levels, indicating leptin resistance. This resistance prevents the brain from accurately sensing fat reserves, disrupting the body's weight regulation.

DOPAMINE'S FUNCTION IN MOTIVATION AND LEARNING

Contrary to popular belief, dopamine's primary role in eating behavior is not pleasure, but rather motivation and learning. Dopamine energizes actions required to obtain food, especially when effort is involved. It also facilitates learning about cues that predict useful outcomes, like food availability. Distinct dopamine systems track internal states, aiding in both rapid associative learning of environmental cues and slower learning about the post-ingestive effects of foods, connecting the sensory experience to bodily needs.

GLP-1 AGONISTS AND THE PHARMACOLOGY OF APPETITE SUPPRESSION

Drugs like Ozempic and Mounjaro, agonists of the GLP-1 hormone, revolutionize obesity treatment by significantly suppressing appetite. The incretin effect, discovered in the 1920s, showed that oral glucose boosts insulin more than IV glucose, originating from the gut. GLP-1, originally identified in Gila monster venom, has pharmaceutical analogs engineered for stability. These drugs act on brainstem centers like the nucleus of the solitary tract and area postrema, significantly reducing food intake beyond physiological levels, leading to substantial weight loss.

GENETICS, ENVIRONMENT, AND THE OBESITY EPIDEMIC

Body weight regulation is highly heritable, with genetics influencing an individual's position on the body weight distribution curve. While human genetics haven't changed rapidly, environmental shifts since the 1970s, such as increased availability of ultra-processed, highly palatable foods, are thought to trigger latent genetic predispositions. Research suggests ultra-processed foods can be consumed in larger quantities, potentially due to differences in nutrient density, texture, and engineered palatability, contributing to the obesity epidemic.

THIRST, SALT APPETITE, AND FLUID HOMEOSTASIS

Separate brain systems control hunger, thirst, and salt appetite, though thirst and salt appetite are more closely linked to maintaining blood osmolality. Thirst is driven by osmosensors in the brain, which detect even minor increases in blood concentration, leading to a strong drive to drink. Fluid intake involves predictive mechanisms, using signals from the mouth and blood osmolarity to quench thirst effectively. This system prioritizes hydration, even potentially overriding hunger signals under conditions of dehydration.

MELANOCORTIN PATHWAY AND FUTURE OBESITY THERAPIES

The melanocortin pathway, involving agouti-related peptide (AgRP) neurons promoting hunger and POMC neurons releasing alpha-MSH that promotes satiety, is a key target for weight regulation. Mutations in this pathway contribute to severe obesity. While developing agonists for the melanocortin 4 receptor has faced challenges due to side effects like increased blood pressure, research continues. Future therapies may involve combined strategies targeting both GLP-1 and melanocortin pathways for enhanced efficacy and safety.

THE PREDICTIVE BRAIN AND NUTRITIONAL LEARNING

The brain constantly makes predictions about future needs, including nutritional states. Our perception of food and its effects is influenced by learned associations between sensory cues and post-ingestive consequences. Information provided about food, such as its nutritional content, can modulate satiety signals. This highlights the complexity of human eating behavior, where cognitive factors interact with physiological drives, and suggests that understanding these predictive mechanisms is crucial for addressing conditions like obesity.

PERSPECTIVES ON DIETING AND FOOD CHOICES

Dr. Knight suggests that simplifying diets to focus on whole foods can naturally reduce intake, partly due to sensory-specific satiety, where repeated exposure to a flavor diminishes appetite for it. Learning also plays a role; we develop preferences for foods associated with positive post-ingestive effects. This might explain why a diet rich in whole, minimally processed foods leads to greater satiety and better appetite regulation, allowing the brain to more accurately match nutrient intake to the body's needs.

OPTIMISM FOR THE FUTURE OF OBESITY TREATMENT

The development of GLP-1 agonists has brought significant optimism to the field of obesity treatment, demonstrating substantial weight loss and unexpected health benefits with good safety profiles. The ongoing research into related compounds, including dual and triple agonists targeting multiple hormones, promises even more effective and personalized therapeutic options. This progress is fueled by a reinvigorated pharmaceutical industry and a deeper understanding of the complex biological systems governing energy balance.

Mentioned in This Episode

●Supplements

●Products

●Software & Apps

●Tools

●Companies

●Organizations

●Books

●Studies Cited

●Concepts

●People Referenced

Common Questions

The brain uses two main systems: a short-term system in the brainstem, which controls meal termination over 10-20 minutes based on gut signals, and a long-term system in the hypothalamus, which tracks body fat levels over weeks to years and modulates the short-term system to match overall energy needs.

Topics

Glp-1 Agonists Health & Longevity Neuroscience & the Brain Nutrition & Diet Mental Health & Psychology Hunger Regulation Weight Management Obesity Treatment Hormonal Regulation Appetite Control Thirst Mechanisms Dopamine In Motivation Leptin Signaling Processed Foods Impact

Mentioned in this video

People

Andrew Huberman

Host of the Huberman Lab podcast and professor of neurobiology and ophthalmology at Stanford School of Medicine.

Zachary Knight

Professor of physiology at the University of California San Francisco and an investigator with the Howard Hughes Medical Institute, specializing in hunger, thirst, and thermoregulation.

Jeff Friedman

Scientist at Rockefeller University who cloned Leptin in 1994, building on earlier work regarding obese mice.

Kevin Hall

A scientist at the NIH known for human obesity research, including experiments hospitalizing people to control diet and measure the effects of ultra-processed vs. whole foods.

Doug Coleman

A scientist at Jackson Labs who hypothesized in the 1950s that obesity in mutant mice was due to a circulating factor (hormone) and its receptor.

Yuming Chen

A graduate student in Dr. Knight's lab who discovered that AGRP neuron activity diminished almost immediately upon a hungry mouse seeing and smelling food, even before the first bite.

Kent Berridge

A colleague at Stanford, though not explicitly mentioned by full name, the expert on 'wanting vs. liking' concepts related to dopamine.

Harvey Grill

Scientist who conducted experiments on 'desate rats' about 50 years ago, demonstrating that the brain stem regulates meal size independent of the forebrain.

Ali Crum

A colleague at Stanford's Psychology Department who studies mindsets and conducted experiments showing that perception (e.g., caloric density of a milkshake) can significantly modulate physiological satiety responses.

B. Anderson

Scientist in the 1950s who discovered osmosensors in the brain by infusing salt into goat brains, leading to extreme water consumption.

Chris Zimmerman

A scientist who recorded thirst neurons in mice and showed that a cold piece of metal on the tongue could temporarily reduce their activity, mimicking the effect of water.

Rudy Leibel

Scientist who conducted a study showing that people who lost significant weight (reduced obese) had substantially lower energy expenditure than individuals of the same body composition who had never been obese.

Richard B. S. Palmiter

Scientist who conducted experiments decades ago showing that mice genetically engineered to lack dopamine still exhibited affective responses to food, indicating dopamine is not necessary for 'liking'.

Organizations

Howard Hughes Medical Institute

A non-profit medical research organization that selects investigators from a competitive pool, placing them in an elite category.

Jackson Labs

A non-profit organization that breeds and distributes mice for scientific research, where spontaneous mutations leading to obese mice were discovered.

Nature

Prestigious scientific journal that published Dr. Knight's paper 'Dopamine subsystems that track internal states'.

FDA

Government agency that requires large cardiac outcome trials for diabetes drugs to measure stroke, heart attacks, and cardiac death.

Companies

BetterHelp

An online platform offering professional therapy with licensed therapists.

Eight Sleep

A company that makes smart mattress covers with cooling, heating, and sleep tracking capabilities.

Millennium Pharmaceuticals

A pharmaceutical company that showed the 'DB gene' mutation was in the leptin receptor.

Products

Pod 4 Ultra

Eight Sleep's newest generation mattress cover with improved cooling, heating, sleep tracking, and snoring detection.

Liraglutide

A GLP-1 drug approved for diabetes in 2010 and weight loss in 2014, with a half-life of about 13 hours, leading to 7-10% weight loss.

Fen-Phen

A diet drug combination from the 1990s that was pulled from the market due to cardiac issues and patient deaths.

Studies & Research

Minnesota starvation experiment

A famous World War II experiment where healthy volunteers were semi-starved to study the effects of caloric restriction on body weight, energy expenditure, and food obsession.

Concepts

Incretin effect

The phenomenon where oral glucose intake produces more insulin release than intravenous glucose, suggesting a gut-derived factor (incretin) amplifies insulin response.

AGRP neurons

A tiny population of neurons in the hypothalamus critical for the appetitive phase of feeding (searching for food) and tracking the body's energy needs. Their activity predicts how much food an animal will eat before taking the first bite.

Vagus Nerve

The major pathway from gut to brain, innervating the stomach, intestines, heart, and lungs, providing neural input about stomach distension and nutrients.

POMC neurons

Companion neurons to AGRP neurons, located in the same hypothalamic region, that promote satiety and have opposing effects on body weight regulation.

Melanocortin 4 receptor

A downstream receptor for POMC products implicated in body weight regulation; mutations in this receptor are common among severely obese individuals.

Nucleus of the solitary tract

A brainstem region that receives direct input from the vagus nerve and is thought to be a key target of GLP-1 drugs for physiological satiety.

Tools & Products

Tirzepatide

A GLP-1/GIP dual agonist drug, marketed as Mounjaro for diabetes and Zepbound for obesity, which is more effective than semaglutide with fewer side effects.

Fiber photometry

A technology allowing researchers to put a fiber optic into an animal's brain to record fluorescence as a readout of neuronal activity, specifically used to study AGRP neurons.

Semaglutide

A GLP-1 drug approved for diabetes in 2017 (Ozempic) and weight loss (Wegovy), with a half-life of 7 days, leading to about 16% weight loss in trials.

Yoga Nidra

Also known as non-sleep deep rest, a practice that restores mental and physical vigor without the tiredness of a conventional nap.

GLP-1

An incretin hormone produced in the intestine that boosts insulin response to glucose and, at pharmacological levels, significantly suppresses appetite and promotes weight loss.

Eli Lilly

The pharmaceutical company that makes the GLP-1/GIP dual agonist tirzepatide (Mounjaro/Zepbound) and is developing a triple agonist.

Amgen

A pharmaceutical company developing an antibody-based dual GLP-1 and GIP inhibitor (AMG 133) for weight loss, which can be given monthly and shows long-lasting effects.

Area postrema

A brainstem region, a circumventricular organ where the blood-brain barrier is weakened, that receives vagal input and is thought to be involved in the nausea side effect of GLP-1 drugs.

Software & Apps

Waking Up App

A meditation app offering guided meditations, mindfulness trainings, and Yoga Nidra sessions.

Drugs & Medications

SGLT2 inhibitors

A class of drugs used for diabetes that block a protein in the kidney, causing glucose to be peed out and leading to weight loss without the individual realizing the energy deficit.

DPP-4 inhibitors

A class of diabetes drugs (e.g., Januvia) that block the enzyme DPP-4, which degrades GLP-1, boosting natural GLP-1 levels three-fold but without significant weight loss.

Exenatide

The first GLP-1 drug approved in 2005 for diabetes, derived from Gila monster venom, with a half-life of about 2 hours.

Supplements

Athletic Greens / AG1

A nutritional insurance policy taken once or twice daily, providing vitamins, minerals, probiotics, and adaptogens to support foundational nutrition and overall well-being.